Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contincengies (Details Textual)

v3.19.1
Commitments and Contincengies (Details Textual)
1 Months Ended 3 Months Ended
Oct. 23, 2018
USD ($)
Jul. 18, 2018
USD ($)
May 29, 2018
Jan. 19, 2017
USD ($)
Jan. 19, 2017
CNY (¥)
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Commitments and Contincengies (Textual)                
Rent expense           $ 22,000 $ 26,000  
Joint venture agreement, description Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed upon milestones.              
Research and development fee           $ 152,460  
Avalon Shanghai Office Lease [Member]                
Commitments and Contincengies (Textual)                
Lease, monthly rent       $ 7,500        
Security deposit       24,500        
Operating lease maintenance fees       $ 600        
Avalon Shanghai Office Lease [Member] | RMB [Member]                
Commitments and Contincengies (Textual)                
Expiration period       Feb. 29, 2020 Feb. 29, 2020      
Lease, monthly rent | ¥         ¥ 50,586      
Security deposit | ¥         164,764      
Operating lease maintenance fees | ¥         ¥ 4,336      
Beijing GenExosome Office Lease [Member]                
Commitments and Contincengies (Textual)                
Expiration period           Mar. 14, 2020    
Lease, annual rent           $ 1,000    
Beijing GenExosome Office Lease [Member] | RMB [Member]                
Commitments and Contincengies (Textual)                
Lease, annual rent           7,000    
Rent expense           43    
Avalon Shanghai [Member]                
Commitments and Contincengies (Textual)                
Joint venture agreement, description     Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (“Unicorn”), pursuant to which a company named Epicon Biotech Co., Ltd. (“Epicon”) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within two years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of March 31, 2019, Avalon Shanghai has contributed RMB 3,000,000 (approximately $0.4 million) that was included in equity method investment on the accompanying consolidated balance sheets.          
AVAR BioTherapeutics (China) Co. Ltd. [Member]                
Commitments and Contincengies (Textual)                
Joint venture agreement, description Avactis Biosciences, Inc. (“Avactis”), a wholly-owned subsidiary of the Company, and Arbele Limited (“Arbele”) agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. (“AVAR”), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the “AVAR Agreement”), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute USD $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis’ cash reserves. Within 30 days, Arbele shall make contribution of USD $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.              
Working capital $ 700,000              
Research and development fee 600,000              
AVAR BioTherapeutics (China) Co. Ltd. [Member] | RMB [Member]                
Commitments and Contincengies (Textual)                
Working capital $ 5,000,000              
Insurance Premium Financing Agreement [Member]                
Commitments and Contincengies (Textual)                
Principal amount   $ 108,528            
Expiration period   May 17, 2019            
Annual interest rate   6.90%            
Outstanding principal balance           $ 22,690   $ 45,088